Stock comparison
Arbutus Biopharma
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ABUS
Arbutus Biopharma
Market cap
$859.29M
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ABUS | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 49D | 79B | HALO |
| Benjamin Graham | 43D | 83A | HALO |
| Philip Fisher | 55C | 65B | HALO |
| Peter Lynch | 48D | 53D | HALO |
| Joel Greenblatt | 100A | 40D | ABUS |
| Charlie Munger | 64D | 80C | HALO |
| Terry Smith | 66B | 84A | HALO |
Side-by-side metrics
| Metric | ABUS | HALO |
|---|---|---|
| Market cap | $859.29M | $8.1B |
| P/E (TTM) | 5.1x | 24.0x |
| EV/EBIT | - | 10.2x |
| ROIC (TTM) | 56.72% | 23.65% |
| Gross margin | 99.98% | 81.24% |
| Net margin | 83.95% | 23.13% |
| Revenue CAGR 5y | 6.4% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | 0.0x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABUS leads on
- EV/EBIT-vs 10.2x+134%
- Debt / Equity0.0xvs 1.0x+100%
- P/E (TTM)5.1xvs 24.0x+79%
- Net margin83.95%vs 23.13%+72%
HALO leads on
- Market cap$8.1Bvs $859.29M+89%
- Revenue CAGR 5y33.23%vs 6.4%+81%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.